Hair Restoration Therapy: The Complete 2026 Clinical Taxonomy

Introduction: Beyond the Norwood Chart

Most hair restoration guidance follows a familiar script. Men are placed on the Norwood scale, women on the Ludwig scale, and each “stage” is matched to a recommended “solution.” The approach is tidy and easy to market, but it skips a more fundamental question that patients need to answer before their stage matters at all.

That question is whether the goal is biological regrowth or visual simulation.

Biological regrowth therapies, including FUE, FUT, PRP, minoxidil, finasteride, and JAK inhibitors, regenerate, preserve, or redistribute living follicles. Visual simulation therapies, such as scalp micropigmentation (SMP) and hair systems, create the appearance of density without altering follicle biology. Both are legitimate, but they serve entirely different objectives.

This article organizes hair restoration therapy into a three-tier clinical taxonomy:

1. Surgical restoration
2. Non-Surgical therapy, separated into FDA-approved and off-label options
3. Adjunctive and Emerging therapies

Visual simulation is then addressed as the parallel half of the taxonomy. Throughout, autoimmune alopecia areata (AA) is integrated alongside androgenetic alopecia (AGA) rather than relegated to a separate discussion. The two conditions frequently intersect in real patients, yet consumer content routinely treats them as unrelated worlds.

For the discerning patient, treatment selection is a clinical decision. It requires an understanding of regulatory status, evidence quality, and realistic outcomes, not a menu of whatever procedure happens to be trending.

The Conceptual Divide Every Taxonomy Should Start With

Biological regrowth therapies act on the follicle itself. They stimulate dormant follicles, block the hormonal or immune processes that miniaturize or attack follicles, or physically relocate living follicles from resistant donor zones to thinning areas.

Visual simulation therapies leave follicle biology untouched. They create an optical effect of density, either through pigment deposits that mimic the shadow of a follicle or through hair systems that add non-biological or donor hair fiber on top of the existing scalp.

This divide is not “real versus fake.” It is “regenerative versus cosmetic.” A patient seeking to restore and protect living hair belongs in a different decision pathway than a patient seeking a specific look with zero downtime. Neither goal is superior; each simply calls for a different family of treatment.

Demand for both families is substantial. Approximately 42% of hair loss sufferers prefer non-surgical solutions, which is precisely why a responsible taxonomy cannot adopt a surgery-first framing.

Within biological regrowth, treatments are further divided into Surgical, Non-Surgical FDA-approved, Non-Surgical off-label, and Adjunctive/Emerging categories. Each category carries a different standard of evidence, and patients deserve to know which standard applies to any treatment they are offered.

Tier 1: Surgical Hair Restoration

Surgical restoration is the most permanent form of biological regrowth. It relocates genetically resistant donor follicles, typically from the back and sides of the scalp, to areas of loss, where they continue to grow for life.

One expectation must be set early: surgery is not a cure for ongoing hair loss. Transplanted follicles are resistant, but the surrounding native hair is not. Without medical therapy to protect non-transplanted hair, progressive loss can continue behind a transplanted hairline, producing an unnatural result over time.

FUE (Follicular Unit Excision)

FUE harvests individual follicular units without a linear incision. The result is no linear donor scar, which makes FUE well suited to patients who prefer short hairstyles or want maximum discretion.

According to the ISHRS 2025 Practice Census, FUE is now used in roughly 85.4% of male and 68.2% of female hair restoration surgeries, making it the dominant surgical technique worldwide.

Technique matters, and so does separating marketing from clinical reality. Most FUE in 2024 and 2025 was performed with motorized hand-held devices (75.1% without suction, 19.8% with suction). Robotic-assisted FUE accounted for only about 1.3% of cases. Despite heavy promotion of robotic and AI-driven harvesting, outcomes continue to depend chiefly on surgeon skill, judgment, and artistry.

For time-conscious professionals, FUE offers meaningful clinical advantages: quick recovery, with most patients returning to normal routines within days, and precise, custom graft placement that supports natural hairline design.

FUT (Follicular Unit Transplantation / Strip Method)

FUT harvests a thin strip of scalp from the donor area, which is then dissected under magnification into individual follicular units. The technique remains highly relevant for patients who require maximum graft yield or extensive coverage in a single session.

FUT is used in about 12.5% of male and 30.0% of female surgical cases. Its greater prevalence among women reflects the fact that many female patients wear longer hairstyles that conceal a donor scar and often prefer not to shave the donor area.

The trade-off is straightforward:

• FUT: a fine linear donor scar, but potentially higher graft yield per session
• FUE: no linear scar and faster recovery, with harvest spread across a wider donor zone

Candidacy, hairstyle preference, and extent of loss should drive this choice, not prevailing trends.

Surgical Candidacy and Patient Profile

Ideal candidates share three characteristics:

• Stable, patterned hair loss
• Adequate donor density
• Realistic expectations about coverage and timing

Poor candidacy flags include:

• Active autoimmune alopecia
• Diffuse, unpatterned hair loss
• Insufficient donor supply

ISHRS data provide useful context for scope and timing. In 2024, 95% of first-time surgical patients began treatment between ages 20 and 35, and the average first procedure involved 2,347 grafts.

Surgical restoration is also not a male-only tier. Women represent the fastest-growing surgical segment: female surgical patients rose 16.5% between 2021 and 2024 and now account for 15.3% of all surgical patients, up from 12.7%.

Beyond the Scalp: Facial and Non-Scalp Hair Transplantation

Facial hair restoration is a distinct surgical sub-category. Advanced FUE technique allows surgeons to sculpt beards, restore mustaches, enhance sideburns, and define jawlines with the same attention to angle and density used on the scalp. Gender-affirming facial hair procedures belong to this surgical branch as well and demand particular sensitivity to facial harmony.

Non-scalp transplantation is rising steadily. In 2024, it was used by 18% of male and 21% of female patients, up from 13% and 17% in 2021. Eyebrows are the top non-scalp site for women (12%), while moustache and beard lead for men (5%).

Comprehensive surgical practices also address scar revision, including donor-area scars from prior procedures, often through a combination of grafting into the scar and other camouflage techniques.

Tier 2: Non-Surgical Therapies (FDA-Approved vs. Off-Label)

The non-surgical tier consists of biologically active, regrowth-oriented treatments delivered through topical, oral, or systemic medication.

The distinction between FDA-approved and off-label use matters clinically. Approval status reflects the depth and type of trial evidence submitted to regulators; it does not, by itself, determine whether a treatment works. Many off-label therapies are supported by strong clinical data and professional consensus. Patients nonetheless deserve transparency about which category a recommended treatment falls into.

This tier also spans two distinct conditions: androgenetic alopecia and autoimmune alopecia areata. A genuine taxonomy must address both.

FDA-Approved Foundations for Androgenetic Alopecia

• Topical minoxidil: FDA-approved since 1988 in 2% and 5% formulations for men and women. It remains the evidence-based foundation of non-surgical AGA care, and the American Academy of Dermatology identifies it as the most commonly used treatment for male pattern hair loss.
• Oral finasteride: the most prescribed hair loss medication among hair restoration physicians, prescribed “always” or “often” by 72% of ISHRS survey respondents in the 2025 Practice Census. It is FDA-approved for men, not women.

For women, the landscape is narrower: topical minoxidil is the only FDA-approved therapy for female pattern hair loss. Given the rapid growth of female patient volume, this gap is an important consideration in treatment planning.

Off-Label Non-Surgical Options for AGA

• Low-dose oral minoxidil (LDOM, roughly 0.25 to 5 mg): off-label but rapidly adopted. Physician use jumped from 26% in the 2022 Census to 65% in the 2025 Census.
• Spironolactone: an off-label anti-androgen used adjunctively, particularly relevant for women.

A 2025 Delphi consensus has informed updated LDOM dosing protocols for women, signaling a maturing standard of off-label care. Off-label prescribing, in this context, is legitimate, physician-guided practice grounded in emerging consensus. It is neither experimental nor unregulated.

FDA-Approved Systemic Therapy for Autoimmune Alopecia Areata

Alopecia areata is an autoimmune condition in which the immune system attacks hair follicles. It is a fundamentally different disease process than AGA, and it now has its own class of FDA-approved systemic treatments: JAK inhibitors, the first-ever approved systemic therapies for severe AA.

• Baricitinib (Olumiant): approved in June 2022 for adults and expanded to adolescents 12 and older in September 2026. In clinical trials, after two years of continuous treatment, 90% of patients had hair regrowth covering 80% or more of the scalp.
• Ritlecitinib (Litfulo): approved in June 2023 for patients ages 12 and older.
• Deuruxolitinib (Leqselvi): an FDA-approved systemic option for adults that rounds out the three-drug class.

This matters directly for the taxonomy. A patient with active alopecia areata is not a candidate for standard AGA-focused surgical or topical regrowth strategies. Misclassification can lead to wasted time, failed grafts, and poor outcomes. Proper diagnosis must precede treatment selection.

Tier 3: Adjunctive and Emerging Therapies

Adjunctive therapies support, amplify, or complement core surgical and non-surgical treatments rather than standing fully alone. Separating this tier from standalone non-surgical therapy helps patients understand what each intervention can realistically contribute.

Innovation investment in this space is considerable. The global hair loss treatment product market is estimated at roughly $3.0 to 5.1 billion in 2026, growing at a 5.5% to 7.2% CAGR, while the broader hair transplant market exceeds $13 billion. That level of activity produces genuine advances, as well as a great deal of hype.

PRP: Surgical Adjunct and Standalone Option

Platelet-rich plasma serves a dual role. As a surgical adjunct, it is used to support graft survival during FUE and FUT. As a standalone option, it is offered as a non-surgical regenerative injection series.

Pooled randomized controlled trial data show that PRP combined with topical minoxidil produced a weighted mean difference of 9.14 hairs/cm² in density versus baseline.

PRP sits squarely at the intersection of adjunctive and non-surgical use, illustrating why rigid category silos can mislead patients.

Low-Level Laser Therapy (LLLT)

LLLT devices were first FDA-cleared for androgenetic alopecia in January 2007 via the 510(k) pathway, following earlier clearances for pain relief, carpal tunnel syndrome, and wound healing. Patients should understand that 510(k) clearance for a device is a different regulatory bar than full drug approval.

The proposed mechanism involves:

• Increased scalp blood flow
• Upregulated ATP production through stimulation of cytochrome C oxidase in follicle mitochondria
• Reduced scalp inflammation

The ISHRS describes LLLT as an option for patients who want to do everything they can for their hair. It is typically layered alongside minoxidil and finasteride or incorporated into post-surgical care.

Microneedling and Nutraceuticals

Microneedling creates controlled micro-injuries that stimulate wound-healing growth factors and enhance absorption of topical treatments such as minoxidil.

Nutraceuticals, including biotin, saw palmetto, and similar supplements, are widely used but supported by limited evidence. Expectations should remain conservative relative to FDA-approved options, and supplements should never replace proven therapy.

Emerging but Unproven: Exosomes and “Stem Cell” Therapies

Exosome therapy is best understood as an emerging biologic amplifier, used alongside FUE or PRP. It is not a standalone, proven treatment.

Patients should be cautious of any clinic marketing exosome or “stem cell” therapies as established or FDA-approved outside of clinical trials. The contrast with minoxidil, finasteride, and JAK inhibitors, each backed by regulatory approval and substantial trial data, is stark.

A trustworthy practice separates hype from evidence rather than upselling unproven biologics. That willingness is itself a meaningful indicator of clinical integrity.

On the Horizon: Clascoterone

Clascoterone, a topical androgen receptor blocker without systemic anti-androgenic effects, is anticipated as a hair loss option around 2027. For patients who wish to avoid finasteride’s systemic effects, it may offer a valuable alternative. Its development signals where non-surgical AGA care is heading: more targeted therapies with fewer systemic trade-offs.

Visual Simulation Therapies: The Other Half of the Taxonomy

Visual simulation is a parallel, equally valid category distinct from every biological regrowth tier above. It is not a lesser option; it pursues a different goal entirely.

These therapies alter appearance only. They do not regenerate or protect existing follicles, and they are not a substitute for medical therapy when biological preservation is also a priority.

Scalp Micropigmentation (SMP)

SMP uses medical-grade pigments to replicate the visual appearance of follicles, mimicking density without any biological change. It is well suited to patients who are not candidates for surgery or simply prefer to avoid it, including those with:

• Donor scars requiring camouflage
• Diffuse thinning
• A preference for a close-shaved aesthetic

SMP also functions across tiers. It can camouflage a FUT donor scar, add the illusion of density behind transplanted grafts, or serve as a complete standalone solution.

Hair Systems

Hair systems, including non-surgical hairpieces and toppers, provide immediate, reversible density without medical intervention. They sit outside biological treatment entirely and should be presented as a legitimate lifestyle choice for certain patients rather than a last resort.

Choosing Between Regrowth and Simulation

A practical decision lens:

• Prioritizing long-term biological hair health: anchor on Tiers 1 through 3.
• Prioritizing immediate appearance, zero downtime, or avoiding needles: consider SMP or hair systems.

These paths are not mutually exclusive. Many patients combine SMP with ongoing minoxidil or finasteride, protecting existing hair while addressing visible thinning immediately.

Putting the Taxonomy to Work: A Clinical Decision Framework

The full taxonomy translates into a practical sequence:

1. Confirm the diagnosis: AGA, alopecia areata, or another cause.
2. Define the goal: biological regrowth, visual simulation, or both.
3. Assess surgical candidacy: stability, donor density, expectations.
4. Layer in FDA-approved non-surgical therapy.
5. Consider off-label and adjunctive options where evidence supports them.
6. Evaluate emerging options with appropriate skepticism.

Surgery and medical therapy are complementary, not either/or. Surgical patients should pair their procedure with FDA-approved or off-label medical therapy to protect non-transplanted hair.

Alopecia areata patients require an entirely different diagnostic and treatment path centered on JAK inhibitors, and they are generally poor candidates for AGA-focused surgery while the disease is active.

Finally, the framework must be applied individually. Rising numbers of female surgical patients, candidates for facial and non-scalp transplants, and patients seeking gender-affirming care each require tailored planning.

Why This Decision Requires a Multi-Specialist Team

No single modality suits every patient. A clinic built around one technique, whether FUE-only or SMP-only, cannot responsibly guide patients across this full taxonomy.

Hair Doctor NYC, operating as Stoller Medical Group, is structured around a team-based model that maps directly onto it:

• Dr. Roy B. Stoller, a double board-certified facial plastic surgeon with more than 25 years of experience and over 6,000 successful hair transplant procedures
• Dr. Louis Mariotti, a double board-certified facial plastic surgeon known for surgical detail and facial harmony
• Dr. Christopher Pawlinga, who has dedicated 18 years exclusively to hair transplantation
• Michael Ferranti, P.A., a licensed SMP specialist with more than 25 years in aesthetic dermatology and plastic surgery

Surgical excellence in FUE and FUT, medical guidance, and visual simulation through SMP are each represented by dedicated expertise, rather than one practitioner spread thin across every category. The practice’s facial plastic surgery foundation also brings a trained eye for proportion to hairline design, facial hair sculpting, and gender-affirming procedures.

Located on Madison Avenue in Midtown Manhattan, the clinic’s “Excellence Meets Elegance” positioning reflects the discreet, quality-focused standards its patients expect. Equally important is the clinical stance outlined throughout this article: a practice that distinguishes FDA-approved from off-label therapy, and openly flags unproven treatments such as exosomes and “stem cell” injections, is acting in the patient’s long-term interest rather than simply selling a procedure.

Conclusion

The most important question in hair restoration is not merely “What Norwood stage am I?” It is “Am I pursuing biological regrowth, visual simulation, or both?” Only after answering that does the choice of tier and modality come into focus.

The three-tier taxonomy (Surgical; Non-Surgical, divided into FDA-approved and off-label; and Adjunctive/Emerging) brings androgenetic and autoimmune alopecia care under one coherent framework, with visual simulation standing alongside as a fully legitimate parallel path.

Informed patients deserve a transparent map of evidence levels and regulatory status before committing to any treatment. That map is the foundation of a result that looks natural today and remains natural for decades.

Schedule a Comprehensive Consultation with Hair Doctor NYC

Patients ready to move from research to a personalized plan can schedule a consultation with Hair Doctor NYC’s multi-specialist team. Each consultation begins with diagnosis and leads to a treatment plan drawn from the full taxonomy, spanning surgical restoration, medical therapy, and scalp micropigmentation.

Rather than steering patients toward a single modality, the team guides each individual across every appropriate option under one Madison Avenue roof. Discretion, personalization, and natural-looking, undetectable outcomes are the standard from the first conversation forward.